ELF3 and ovarian carcinoma: The identification of ELF3 as a favorable prognostic marker that can predict ovarian cancer patient survival will enable us to develop novel therapeutic regimens by upregulating ELF3 and introduce novel biologic therapy or chemotherapy for ovarian cancer at the time of initial diagnosis if patients can be identified up front based on the ELF3 expression levels in their tumors.